Course of coronary heart disease in patients with cardiovascular renal metabolic syndrome and separately metabolic

Introduction. Renal dysfunction is increasingly recognized as a key mediator of the association between metabolic risk factors and cardiovascular disease (CVD). Therefore, rather than simply viewing cardiorenal (CR) syndrome and cardiometabolic (CM) diseases as separate conditions, it is clear that we need to consider them as the broader concept of cardiovascular-renal-metabolic syndrome (CVMS). Purpose of the study: Studying the differences in the influence of SSMPS and separately metabolic (MS) on the course of coronary heart disease (CHD). Materials and methods. The study included 116 patients - 69 (59.5 %) men and 47 (40.5 %) women who were treated at the RCH Hospital No. 2 from 2022 to 2023. The patients were divided into two groups, the 1st group included n = 52 with cardiovascular-renal-metabolic syndrome, the 2nd group included n = 64 with metabolic syndrome. The duration of the study is 18 months. Results. Primary indicators of low-density lipoproteins (LDL) in the 1st group were 2.9 ± 3.6 in the 2nd group 2.6 ± 4.0 p < 0.05, and upon re-examination, the ratio of values was as follows - 3 .2 ± 2.8 to 3.0 ± 3.3 p > 0.05. Patients with type 2 diabetes mellitus (DM2) increased by the end of the examination in both groups, but not so significantly in relation to the total weight of 2.6 % to 3.4 % p < 0.05. During the repeated examination, the indicators of arterial hypertension (AH) of the 2nd degree prevailed (34.6 % to 32.8 %) p < 0.05, and there was also an increase in patients with hypertension of the 3rd degree (25.0 to 25.0) p < 0.05, mainly due to patients of the 1st group with kidney disease. Re-admission to the hospital occurred more often in patients with SSPMS than in the group with MS 9.5 ± 7.2 and 12.6 ± 6.8 months, p < 0.05. In-hospital mortality from acute myocardial infarction (AMI) slightly prevailed in group 1 upon re-admission to hospital, ratio n = 3 (5.8 %), in group 2 n = 1 (1.6 %), p > 0.05. Conclusions. In conclusion, our nonrandomized prospective study showed that patients with cardiovascular-renal-metabolic syndrome are at a higher risk of developing cardiovascular events than patients with metabolic syndrome alone. Analysis of lipid metabolism in the group of cardiovascular-renal-metabolic syndrome showed that in a short time after discharge from the hospital, from 6 months to 1.5 years, the indicators of total cholesterol, triglycerides and lowdensity lipoproteins progress negatively to the time of relapse of angina pectoris.